2025
NOVEMBER
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 11
105
ROLE OF ENDOTHELIAL DYSFUNCTION IN THE DEVELOPMENT OF
HYPERTENSIVE RETINOPATHY
Jalalova Dilfuza Zuhridinovna
Scientific supervisor.
Department of Ophthalmology, Samarkand State Medical University
Istamova Moxinbonu
Samarkand State Medical University, Department of Ophthalmology, 1st year clinical ordinator
https://doi.org/10.5281/zenodo.17587161
Annotation.
Endothelial dysfunction (ED) plays a central role in the pathophysiology of
hypertensive retinopathy, serving as an early marker and a contributing mechanism in the
microvascular damage associated with chronic hypertension. This study investigates the
correlation between systemic endothelial dysfunction markers—such as nitric oxide (NO),
endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF)—and the progression of
hypertensive retinopathy in patients at different stages of arterial hypertension. A total of 120
hypertensive patients were examined using clinical, laboratory, and ophthalmologic methods
including fundus photography, optical coherence tomography (OCT), and measurement of plasma
biomarkers. The results demonstrated a strong association between impaired endothelial
homeostasis and retinal microangiopathy, confirming that endothelial dysfunction precedes
visible retinal changes. Early detection and correction of endothelial dysfunction may thus serve
as an effective strategy for preventing or slowing hypertensive retinopathy progression,
preserving vision, and reducing cardiovascular risk.
Keywords:
endothelial dysfunction, hypertensive retinopathy, nitric oxide, endothelin-1,
VEGF, microcirculation, vascular remodeling.
Introduction
Hypertensive retinopathy represents one of the most common microvascular
complications of systemic arterial hypertension. It reflects the structural and functional changes in
the retinal circulation that occur due to chronic elevation of blood pressure. Among the various
mechanisms involved, endothelial dysfunction has emerged as a key pathophysiological link
between systemic hypertension and retinal vascular damage.
The vascular endothelium is responsible for maintaining vascular tone, permeability, and
hemostasis through the release of vasoactive substances such as nitric oxide (NO) and endothelin-
1 (ET-1). In the hypertensive state, increased oxidative stress and reduced bioavailability of NO
lead to endothelial dysfunction, promoting vasoconstriction, inflammation, and vascular
remodeling. These alterations contribute to the narrowing of retinal arterioles, increased vascular
permeability, and the development of hemorrhages, microaneurysms, and exudates typical of
hypertensive retinopathy.
Moreover, elevated levels of VEGF further exacerbate vascular leakage and
neovascularization in severe cases. Understanding the role of endothelial dysfunction in the onset
and progression of hypertensive retinopathy is crucial for identifying early diagnostic markers and
therapeutic targets. This study aims to evaluate endothelial biomarkers and correlate them with
clinical and ophthalmologic findings to establish their predictive value in hypertensive retinopathy.
2025
NOVEMBER
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 11
106
Materials and Methods
The study included 120 patients aged 35–70 years diagnosed with
essential hypertension, divided into three groups according to the Keith-Wagener-Barker
classification of hypertensive retinopathy: Group I (mild, n=40), Group II (moderate, n=40), and
Group III (severe, n=40). The control group consisted of 30 normotensive individuals matched by
age and gender. Ophthalmologic examination involved visual acuity testing, slit-lamp
biomicroscopy, and fundus evaluation using digital fundus photography. Retinal thickness and
structural changes were assessed by OCT. Blood samples were collected for measuring plasma
NO, ET-1, VEGF, and malondialdehyde (MDA) levels using enzyme-linked immunosorbent
assay (ELISA). Endothelial function was also evaluated by flow-mediated dilation (FMD) of the
brachial artery using high-resolution ultrasound. Statistical analysis was conducted using SPSS
26.0 with significance set at p<0.05. Correlations between endothelial markers and retinopathy
grades were determined using Pearson’s correlation coefficient, and multivariate regression
analysis identified independent predictors of retinal changes.
Results
The findings demonstrated a progressive decline in plasma NO levels and FMD
percentages with increasing severity of hypertensive retinopathy (p<0.001). Mean NO
concentration was 42.3±6.1 µmol/L in Group I, 29.8±5.4 µmol/L in Group II, and 21.4±4.9
µmol/L in Group III, compared to 61.2±7.3 µmol/L in the control group. Conversely, ET-1 and
VEGF levels showed a significant elevation across groups, indicating heightened vasoconstrictive
and angiogenic activity. Mean ET-1 levels increased from 3.2±0.7 pg/mL in controls to 9.1±1.2
pg/mL in Group III (p<0.001), while VEGF rose from 122.5±15.6 pg/mL to 268.9±22.3 pg/mL
(p<0.001). OCT analysis revealed that central retinal thickness increased proportionally with the
severity of retinopathy, correlating strongly with VEGF and MDA levels (r=0.71, p<0.01).
Multivariate analysis identified ET-1 and VEGF as independent predictors of retinal
structural alteration. Patients receiving combined antihypertensive and antioxidant therapy showed
partial restoration of endothelial function and stabilization of retinal findings over a 12-month
follow-up period. These results confirm that systemic endothelial dysfunction not only mirrors but
also contributes to the retinal vascular pathology seen in hypertensive retinopathy.
Discussion
The data from this study support the hypothesis that endothelial dysfunction is
both a biomarker and a pathogenic factor in hypertensive retinopathy. Reduced NO bioavailability
and increased ET-1 and VEGF levels create an imbalance between vasodilation and
vasoconstriction, leading to microvascular injury. The interplay of oxidative stress, inflammation,
and impaired endothelial repair mechanisms accelerates vascular remodeling and disrupts the
blood-retina barrier. These processes underlie the morphological features observed in fundus
examinations, including arteriolar narrowing, hemorrhages, and exudates. The strong correlation
between systemic endothelial markers and retinal damage suggests that endothelial assessment can
serve as an early diagnostic tool before visible ocular changes occur. Therapeutic interventions
aimed at restoring endothelial function—such as ACE inhibitors, angiotensin receptor blockers,
statins, and lifestyle modifications—may offer protective effects on the retinal vasculature.
Additionally, the integration of non-invasive endothelial function testing into routine
hypertensive care could improve risk stratification and disease monitoring. Early detection and
management of endothelial dysfunction are likely to reduce not only ocular complications but also
systemic cardiovascular events, given the shared microvascular pathology.
2025
NOVEMBER
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 11
107
Conclusion
Endothelial dysfunction plays a fundamental role in the pathogenesis of
hypertensive retinopathy. The imbalance between vasodilatory and vasoconstrictive factors leads
to microvascular remodeling, increased vascular permeability, and progressive retinal damage.
Monitoring biomarkers such as NO, ET-1, and VEGF provides valuable insights into
disease progression and treatment response. Early correction of endothelial dysfunction through
pharmacologic and lifestyle interventions can prevent or delay retinal complications and improve
visual and systemic outcomes in hypertensive patients. Thus, endothelial health should be a
primary focus in the prevention and management of hypertensive retinopathy.
References
1.
БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ.
2.
Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических
кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от
иммунного статуса пациентов. междисциплинарный подход по заболеваниям
органов головы и шеи, 103.
3.
ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И Д-
ДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ
ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL
SCIENCES 3.3 (2024): 300-307.
4.
Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal
microcirculation in patients with uncomplicated arterial hypertension International
Ophthalmological Congress IOC Tashkent 2021.
5.
Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients
with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume
No., No. WITH.
6.
Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал
гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг
маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210.
7.
Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and
eye pathology. Science and innovation, 1(8), 91-100.
8.
Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE
VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL
MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European
journal of molecular medicine, 2(5).
9.
Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и
хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216.
10.
Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки
при артериальной гипертензии. In Международная научная конференция
Университетская наука: взгляд в будущее (pp. 56-64).
11.
Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З.
(2016). Эффективность комбинированного лечения пациентов с центральной
2025
NOVEMBER
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 11
108
серозной
хориоретинопатией.
Вестник
Башкирского
государственного
медицинского университета, (2), 64-66.
12.
Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у
пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет».
Тошкент-2022, Том №, №. С.
13.
Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной
микроциркуляции у пациентов с неосложненой артериальной гипертензией/I
Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96.
14.
Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS,
APPEARANCE, TREATMENT OF VARICOSE VEINS.
15.
Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал
гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг
маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210.
16.
Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases,
changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22.
17.
Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal
fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific
Research Journal. ISSUE, 2, 958-963.
18.
Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular
system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply
deficiency. Science and innovation, 1(Special Issue 2), 515-522.
19.
Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive
retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2,
949-952.
20.
Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической
ретинопатии. Врач-аспирант, 37(10), 864-868.
21.
Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у
пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41,
33-36.
22.
ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ РЕТИНОПАТИИ НА
ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ ТОМОГРАФИИ. SCIENTIFIC
JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 336-342.
23.
ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА ЗРЕНИЯ У
ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ СЕТЧАТКИ.
SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 286-293.
24.
ЖД, З. (2024). ОЦЕНКА КЛИНИЧЕСКИХ И ФУНКЦИОНАЛЬНЫХ ПОКАЗАТЕЛЕЙ
ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С
АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL
SCIENCES, 3(3), 330-335.
25.
Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при
артериальной гипертензии. Miasto Przyszłości, 41, 37-40.
